-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PH-006 in Allergic Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-006 in Allergic Conjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-006 in Allergic Conjunctivitis Drug Details: PH-006 is under development for the...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Corneal Ulcers – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Ulcers - Drugs In Development, 2023’, provides an overview of the Corneal Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Allergic Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Allergic Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Retinal Vascular Occlusion – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Vascular Occlusion - Drugs In Development, 2023’, provides an overview of the Retinal Vascular Occlusion pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Vascular Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Retinal Vein Occlusion – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Vein Occlusion - Drugs In Development, 2023’, provides an overview of the Retinal Vein Occlusion pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...